Trial Profile

Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ponatinib (Primary) ; Antineoplastics
Indications Chronic myeloid leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms MATCHPOINT

Most Recent Events

14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
06 Nov 2019 Results (n=17) presented in the 61st Annual Meeting and Exposition of the American Society of Hematology.
09 Oct 2018 Planned End Date changed from 15 Sep 2017 to 26 Apr 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com